IQVIA Holdings Inc. (NYSE:IQV) Shares Acquired by Marks Group Wealth Management Inc

Marks Group Wealth Management Inc boosted its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 33.2% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 45,915 shares of the medical research company's stock after acquiring an additional 11,449 shares during the period. Marks Group Wealth Management Inc's holdings in IQVIA were worth $8,095,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the company. Continuum Advisory LLC lifted its stake in shares of IQVIA by 3.7% during the fourth quarter. Continuum Advisory LLC now owns 1,803 shares of the medical research company's stock worth $354,000 after buying an additional 64 shares during the period. Ballentine Partners LLC raised its stake in IQVIA by 4.9% in the 1st quarter. Ballentine Partners LLC now owns 1,477 shares of the medical research company's stock worth $260,000 after acquiring an additional 69 shares during the last quarter. ST Germain D J Co. Inc. lifted its position in IQVIA by 66.1% during the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after acquiring an additional 76 shares during the period. Zions Bancorporation N.A. grew its stake in IQVIA by 55.2% during the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company's stock valued at $47,000 after purchasing an additional 85 shares during the last quarter. Finally, Quadrant Capital Group LLC increased its holdings in shares of IQVIA by 10.7% in the fourth quarter. Quadrant Capital Group LLC now owns 928 shares of the medical research company's stock valued at $182,000 after purchasing an additional 90 shares during the period. 89.62% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently commented on IQV shares. Redburn Partners set a $188.00 target price on IQVIA in a research report on Friday, May 23rd. HSBC downgraded shares of IQVIA from a "buy" rating to a "hold" rating and dropped their price objective for the company from $260.00 to $160.00 in a report on Friday, April 25th. Evercore ISI boosted their target price on shares of IQVIA from $170.00 to $180.00 and gave the company an "outperform" rating in a research report on Wednesday. Citigroup reaffirmed a "neutral" rating on shares of IQVIA in a research report on Thursday, May 22nd. Finally, JPMorgan Chase & Co. lowered their target price on IQVIA from $232.00 to $177.00 and set an "overweight" rating on the stock in a research note on Monday, May 19th. Eight analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, IQVIA presently has an average rating of "Moderate Buy" and a consensus price target of $222.45.

IQVIA Price Performance

Shares of IQV stock traded down $2.80 on Friday, reaching $162.73. 1,156,699 shares of the company were exchanged, compared to its average volume of 1,660,352. IQVIA Holdings Inc. has a 1 year low of $134.65 and a 1 year high of $252.88. The company has a debt-to-equity ratio of 2.19, a quick ratio of 0.82 and a current ratio of 0.82. The business has a 50-day moving average price of $151.96 and a 200 day moving average price of $171.98. The company has a market cap of $28.15 billion, a price-to-earnings ratio of 22.17, a P/E/G ratio of 1.81 and a beta of 1.30.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, topping the consensus estimate of $2.63 by $0.07. The company had revenue of $3.83 billion during the quarter, compared to analyst estimates of $3.77 billion. IQVIA had a return on equity of 29.16% and a net margin of 8.61%. IQVIA's quarterly revenue was up 2.5% on a year-over-year basis. During the same period in the previous year, the business earned $2.54 EPS. Equities research analysts forecast that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.